Navigation Links
Bradmer to present at the 10th Annual BIO CEO & Investor Conference
Date:2/8/2008

TSX: BMR

TORONTO, Feb. 8 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will participate as a presenter and panelist at the 10th Annual BIO CEO & Investor Conference. Dr. Ezrin will provide an update on the Company's preparations for the planned Phase III trial for Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer. The conference is being held at the Waldorf Astoria Hotel in New York City and Bradmer's corporate presentation is scheduled on Tuesday, February 12th at 2:45 PM ET in the Bleekman Suite. Dr. Ezrin will also be a panelist at the Neuro-Oncology Workshop, Neuro-oncology: "Breaking Down the Barriers to New Neuro-Oncology Drugs" session on Monday, February 11th from 9:30 to 10:55 AM ET in the East Foyer.

For more information on the BIO CEO & Investor Conference, visit the conference website at http://ceo.bio.org.

About Bradmer Pharmaceuticals Inc. (http://www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, the receipt of all regulatory approvals required to conduct the proposed clinical trial of Neuradiab, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bradmer announces additions to Scientific Advisory Board
2. Bradmer Medical Isotope Supply For Phase III Trial Secure
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. Bradmer provides Phase III Neuradiab trial update and guidance
5. Bradmer announces management changes
6. Mark Wylie and Suzy Preston Hoover Bring The Biggest Loser Million Pound Tour, Presented by MSN, to Dadeland Mall
7. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
8. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
9. Assurant President and Chief Executive Officer Robert B. Pollock to Present at Merrill Lynch Insurance Investor Conference on February 12
10. CorVel to Present at UBS Global Healthcare Services Conference
11. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... heart-wrenching story of child abuse and neglect, and the struggles faced while hoping ... is the creation of published author, Judy Von Bernewitz, who spent 13 years ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... Stewart is the Founder and Managing Member for t4 Leadership Development & Consulting. ... critical to his definition of “success”: physician leadership development, servant leadership, data driven ...
(Date:8/22/2017)... ... 22, 2017 , ... Although Labor Day is not as popular for fireworks ... weekend displays, and numerous households celebrate the unofficial end of summer with backyard fireworks ... pets. , Kris Zambo, owner of Dynamite Fireworks in Hammond, Indiana, ...
(Date:8/21/2017)... ... August 22, 2017 , ... The National ... a 2017-2018 inductee into its VIP Woman of the Year Circle. She is ... leading networking organization exclusively for professional women, boasting more than 850,000 members, a ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... has become the Official Technology Partner of North Country Region Volleyball and will ... Systems) volleyball software, along with providing sport management software to their member clubs. ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... N.J. , Aug. 17, 2017 Bio-Ess Laboratories, LLC Chief ... increase antibody titer and present new data on Cell-Ess® Universal ... in Boston, MA August 21-25.  The Bioprocessing Summit ... today,s bioprocess challenges. ... and Optimizer ...
(Date:8/15/2017)... 2017 AccuGenomics, Inc., a diagnostic company based ... that the company has provided an AccuKit to the ... at Chapel Hill and to Qura Therapeutics for evaluation ... quantify HIV reservoir and viral expression in human CD4+ ... Cure Center is a joint initiative between the University ...
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
Breaking Medicine Technology: